For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Source: 
Endpoints
snippet: 

The battle over whether Biogen’s Alzheimer’s drug Aduhelm actually helps patients may never end, but in a recent SEC filing, Biogen, at least for accounting purposes, now says its $230 million stash of Aduhelm should be considered worthless.